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Abstract
Background: Trachoma is the leading infectious cause of blindness due to conjunctival infection with Chlamydia
trachomatis. The presence of active trachoma and evidence of infection are poorly correlated and a strong immunologically-
mediated inflammatory response means that clinical signs last much longer than infection. This population-based study in
five Aboriginal communities endemic for trachoma in northern Australia compared a fine grading of clinical trachoma with
diagnostic positivity and organism load.
Methods: A consensus fine grading of trachoma, based on clinical assessment and photograding, was compared to PCR, a
lipopolysacharide (LPS)-based point-of-care (POC) and a 16S RNA-based nucleic acid amplification test (NAAT). Organism
load was measured in PCR positive samples.
Results: A total of 1282 residents, or 85.2% of the study population, was examined. Taking the findings of both eyes, the
prevalence of trachomatous inflammation-follicular (TF) in children aged 1–9 years was 25.1% (96/383) of whom 13 (13.7%)
were PCR positive on the left eye. When clinical data were limited to the left eye as this was tested for PCR, the prevalence of
TF decreased to 21.4% (82/383). The 301 TF negative children, 13 (4.3%) were PCR positive. The fine grading of active
trachoma strongly correlated with organism load and disease severity (rs=0.498, P=0.0004). Overall, 53% of clinical activity
(TF1 or TF2) and 59% of PCR positivity was found in those with disease scores less than the WHO simplified grade of TF.
Conclusion: Detailed studies of the pathogenesis, distribution and natural history of trachoma should use finer grading
schemes for the more precise identification of clinical status. In low prevalence areas, the LPS-based POC test lacks the
sensitivity to detect active ocular infection and nucleic acid amplification tests such as PCR or the 16S-RNA based NAAT
performed better. Trachoma in the Aboriginal communities requires specific control measures.
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Introduction
Trachoma is the leading infectious cause of blindness [1,2,3], and
results from repeated episodes of conjunctival infection by Chlamydia
trachomatis (CT) serovars A, B, Ba and C. It is a major public health
problem associated with poverty in environments with inadequate
sanitation, poor personal hygiene and poor water supply and is now
largely confined to developing countries, particularly in Sub-
Saharan Africa [2,4,5,6]. Nucleic acid amplification tests (NAATs)
require appropriate facilities and skilled staff, but a assay designed
for use in resource-limited settings may offer some advantages for
the diagnosis of infection over clinical assessment [7,8]. In general,
irrespective of the diagnostic methodology, there is a relatively poor
correlation between clinically active trachoma and biological
evidence of infection, in part because signs of the disease are
induced by a strong immunologically-mediated inflammatory
response that resolves much more slowly than the infection
[4,5,9,10,11,12,13]. It is further compounded by the occurrence
of repeated episodes of infection. Also important is the relative lack
of precision in assessing clinical status with the WHO simplified
trachoma grading system [14,15], which was designed to be learnt
and used by local health workers and generally has a high level of
reproducibility [16].
We sought to compare a fine consensus grading of trachoma
combining clinical and photographic grading [15,17] with a
commercially available polymerase chain reaction (PCR), the CT/
NG Amplicor test (Roche Diagnostic Corporation, IN, USA). We
sought to compare field performance of a previously described
POC assay [7] and a sensitive in-house 16S-RNA NAAT using an
improved visual detection of nucleic acid by dipstick [18,19] using
the CT/NG Amplicor assay targeting one sequence coding for
ORF1 (Open Reading Frame 1) of the Chlamydia cryptic plasmid
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quantitative PCR (qPCR) in CT positive individuals [20,21].
Methods
Patients
Patients were recruited using the medical clinical list, the local
council housing list and local knowledge of the Aboriginal Health
Workers from five Aboriginal communities with endemic trachoma
in the Katherine region of the Northern Territory Australia during
a five week period over July and August 2007 as described
previously [15,17]. These communities had not received any recent
azithromycin or other mass antibiotic treatment, although local
health services do prescribe and dispense a range of broad-spectrum
antibiotics on an individual patient basis that might indirectly have
had an impact on trachoma and our findings. However, without
access to confidential patient history, the recipients of these
antibiotic prescriptions were not identifiable. In principle, school
children in remote communities receive one annual health check
that includes trachoma screening, but this process is patchy at best.
Despite recommendations, very little screening for trichiasis in
elders has been conducted in area where trachoma is endemic [15].
During the clinical assessment, both examiners wore two pairs
of gloves. To limit the risk of cross-contamination between
specimens and to prevent the exposure to transmittable diseases to
consecutive subjects, utensils and surfaces [5], the outer pair was
removed between successive participants and the inner pair
disinfected and regularly disposed of. The examiner graded the
clinical signs of trachoma using a fine grading scheme (Table 1)
[15,17]. Digital photographs were taken of the left inverted upper
lid that were subsequently graded independently using the fine
grading scheme and any discrepancies were adjudicated to give
the final consensus grading [15,17]. The clinical grading was also
expressed in terms of the WHO simplified grading system as
‘‘Trachomatous inflammation-follicular’’ (referred to as TFWHO),
‘‘Trachomatous inflammation-intense’’ (TIWHO) and ‘‘Trachoma-
tous scarring’’ (TSWHO) [14].
After the clinical assessment and photography, two ocular swabs
from the left eye were collected consecutively under stringent
conditions to limit cross-contamination [5], and rigorous photo-
graphic cataloguing and sample labelling systems. Over 95% of
Author Summary
Repeated episodes of C. trachomatis infection lead to
active trachoma clinically characterised by an often
intense inflammatory response to chlamydial antigens
with later scarring and distortion of the eyelid leading to
blindness. However, the clinical signs of trachoma do not
correlate well with laboratory tests to detect the presence
of Chlamydia. The WHO simplified clinical grading scheme
currently used for assessment of trachoma has a poor
correlation with C. trachomatis genomic test findings,
even though the detection of bacterial genome is
strongly correlated with the prevalence and severity of
active trachoma. A detailed assessment of the clinical
signs using a finer grading system was studied in a
population-based survey in five Australian Aboriginal
communities. Much clinical activity and infection was
found in those with clinical signs below the threshold
used in the current WHO grading scheme. Future studies
of the distribution of infection and pathogenesis should
use finer grading methods than the current WHO scheme.
The prevalence of trachoma in these communities
confirms that trachoma remains of public health impor-
tance and sustained interventions to control trachoma are
warranted.
Table 1. Detailed grading scheme for clinical assessment of trachoma.
Grading Definition of the finer grading
TF - Trachomatous follicular:
TF0 No visible follicles in the upper tarsal conjunctiva
TF1 One or two small follicles in the upper tarsal conjunctiva
TF2 More than two but less than 5 follicles of 0.5 mm in diameter in the upper tarsal conjunctiva
TF3 Five or more follicles of 0.5 mm in diameter in the upper tarsal conjunctiva and equivalent to WHO simplified
grading of TF
TF4 Extensive large follicles of 0.5 mm in diameter in the upper tarsal conjunctiva
TI - Trachomatous inflammation – intense
TI0 No visible inflammation of the tarsal conjunctiva
TI1 Mild inflammation of the tarsal conjunctiva without obstruction of the vessels
TI2 Moderate inflammation of the tarsal conjunctiva with less than half of the deep tarsal vessels being obscured
TI3 Pronounced inflammatory thickening of the tarsal conjunctiva that obscures more than half of the normal deep
tarsal vessels and equivalent to WHO simplified grading of TI
TI4 Very pronounced inflammation of the tarsal conjunctiva
TS - Trachomatous scarring
TS0 No visible scarring of the tarsal conjunctiva
TS1 Small amount of early scarring apparent, but not clearly visible
TS2 Moderate amount of early scarring apparent, but not clearly visible
TS3 Presence of clearly visible scarring apparent in the upper tarsal conjunctiva and equivalent to WHO simplified
grading of TS
TS4 Extensive clearly visible scarring involving most of the tarsal conjunctiva
doi:10.1371/journal.pntd.0000986.t001
Correlation of Clinical Trachoma and Infection
www.plosntds.org 2 March 2011 | Volume 5 | Issue 3 | e986samples were collected by the same swabber throughout the study
to minimise any sampling variability. Additionally, gloves,
surfaces, loupes, the camera and other utensils were swabbed
twice a day to detect possible cross-contamination.
We obtained approval for the study from the Human Research
Ethics Committees of the Royal Victorian Ear and Eye Hospital,
the Australian National University, the Northern Australian
National University and the Northern Territory Government
Department of Health & Communities Services and Menzies
School of Health Research. Signed written consent was obtained
from each person, with consent for children under 18 years of age
being provided by a parent or guardian [15,17].
Clinical examination
Clinical assessment can be difficult and inconsistent when
conducted by poorly trained or inexperienced staff [5,22]. Taking
digital photographs, was previously described as an alternative
method and compared to clinical assessment [15,22]. Briefly, the
majority of the examinations and taking digital photographs was
done by examiner A (96%) to minimise inter-observer variability
while the remaining examination were performed by examiner B
who also examined and graded independently digital photographs
without prior knowledge of the clinical assessment. In a masked
fashion, both examiners re-examined photographs and gave an
adjudicated score when either the clinical grade or the
photographic grade was 3 or greater. A total of 88, 29 and 93
photographs were re-examined for the presence of follicles,
inflammation and scarring, respectively. Weighted kappa analysis
was previously reported to determine the concordance between
methods. The data indicated that there was 79.7% agreement
(kappa=0.40) between clinical assessment, clinical grading and
photographic assessment of trachomatous follicles (TF1-TF4) and
96.1% agreement (k=0.71) when the fine score was translated to
TFWHO. The agreement for TIWHO, and TSWHO was 89.3%
(k=0.67) and 92.7% (k=0.67), respectively [15]. Previous studies
have shown the advantages of using finer scales to enhance the
sensitivity of clinical measurement, although finer grading schemes
may reduce the concordance, or frequency of perfect agreement,
between the grades assigned by pairs of independent observations
[23].
Laboratory assays
The POC test was performed on site using the first left-eye
ocular swab collected by only one experienced technician
throughout the study. The assay detects chlamydial lipopolysac-
charide (LPS) as previously described [7] with the following
modifications for field use: 1) an alternative nitrocellulose
membrane was used as the manufacturer discontinued the
membrane previously used, 2) the ratio of lyophilised signal
amplification system was modified for the test to function at high
ambient temperature and 3) increased length of the conjugate tube
which houses the dipstick to minimise the evaporation of the
reagents during wicking and to protect the membrane against dust.
In addition to the lyophilised signal amplification reagents
consisting of a biotin-labelled monoclonal antibody to chlamydial
LPS and an anti-biotin monoclonal antibody conjugated to
colloidal gold particles as colour indicator [7], the nitrocellulose-
based membranes are the heart of lateral or vertical flow assays.
The wicking rate, pore size, residual surfactants and detergents
present on the matrix affect the characteristics of nitrocellulose-
based membranes and reaction kinetics. Therefore, changing this
porous substrate matrix and the addition of some features (i.e.
shape of the conjugate tube) require a systematic adjustment of
ratio of the lyophilized signal amplification reagents.
The anti-biotin monoclonal antibodies (clone BII-10A12A9A1,
Diagnostic Development Unit, University of Cambridge, Cam-
bridge, UK) conjugated to colloidal gold (British Biocell
International, Cardiff, UK) by passive adsorption specifically bind
to the lyophilised signal amplification reagents, consisting of a
biotinylated monoclonal antibody to chlamydial LPS detection
antibody (clone CTIII-10B9A10A4D28, Diagnostic Development
Unit) biotinylated with the BAC-Sulfo-NHS-LC-biotin reagent
(Sigma, St Louis, MO, USA) at a ratio of nine biotins per antibody
molecule.
For LPS-POC testing, ocular swabs were placed in the sample
extraction tube with a tapered bottom to facilitate extraction of the
swab and a cap that allows it to also function as a dropper. The
lysis reagent and analyte stabiliser were added sequentially as
previously described [7]. Briefly, the lysis reagent (400 mL,
Diagnostic Development Unit) and analyte stabiliser (300 mL,
Diagnostic Development Unit) were added sequentially and mixed
by gently dipping the swab to the bottom of the extraction tube
three times after addition of each reagent. Two hundred
microlitres of the above extract were immediately transferred to
800 mL of pre-dispensed Amplicor sample dilution buffer (Roche)
for PCR testing. Thereafter, the signal enhancer reagent (33 mL,
Diagnostic Development Unit) was added to each extract. This
allows the release of chlamydial-LPS for detection. Five drops of
the resulting extract (100 mL) were transferred to the detection
tube into which the dipstick is placed. Two hundred microlitres of
the above extract were immediately transferred to 800 mL of pre-
dispensed Amplicor sample dilution buffer (Roche) for PCR
testing. Thereafter, the signal enhancer reagent was added to each
extract. This allows the release of chlamydial-LPS for detection.
Five drops of the resulting extract were transferred to the detection
tube into which the dipstick is placed. The detection tube contains
lyophilised reagents of the signal amplification system consisting of
biotinylated monoclonal antibody to chlamydial LPS and anti-
biotin monoclonal antibodies conjugated to colloidal gold particles
as the colour indicator. The dipstick contains a nitrocellulose
membrane, lined with another monoclonal antibody to chlamyd-
ial-LPS (clone CVII-105A5A8, Diagnostic Development Unit) at
the capture zone, which captures the immune complex formed
between the chlamydial-LPS and signal amplification system
reagents, if present. The accumulation of coloured conjugate at
the capture line of the dipstick generates a visible colour change as
previously described [7]. To generate a visual signal on the parallel
to and above the capture zone, the dipstick was lined with the anti-
biotin antibody described above, which served as the procedural
control zone. All antibodies were produced in-house and purified
by affinity chromatography to more than 95% purity before use.
For PCR testing, 200 mL of the POC extract, obtained before
adding 6% H2O2, were mixed with 800 mL of Amplicor sample
dilution buffer (Roche) and placed at 4 uC within 1 hr, and frozen
at –20 uC within 2 days until transport to Cambridge, UK in dry-
ice. These samples were stored at –80 uC until blind-tested by
Amplicor.
The second matched swab was stored dry on cold packs, frozen
at –20 uC within 2 days of collection and transported to
Cambridge, UK in dry ice, and stored at –80 uC until tested to
minimise any target degradation. For chlamydial and internal
control testing, they were placed overnight in the Amplicor
M4RT-transport medium (3 mL, Roche) and tested by one
experienced technician according to the manufacturer’s instruc-
tion (Roche).
All samples yielding a positive PCR result were quantified by
previously described ethanol precipitation and qPCR methods
[20,21]. Briefly, homogenized M4RT-media (500 mL) from an
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the ocular swab were aliquoted into a DNase/RNase free
siliconized tube (BioQuote, North Yorkshire, UK). Specimens
were incubated at room temperature for 10 min prior to
centrifugation at 17,860 g (max speed: 15,000 rpm) for 15 min
at 25 uC (1.0R Megafuge). Supernatants obtained from diluted
M4RT-media were decanted with sterile filter tips and the
resulting pellets were re-suspended in 1 ml of cell culture grade
Dulbecco’s phosphate-buffered saline (DPBS) lacking Ca
2+ and
Mg
2+ (BioWhittaker, Walkersville, MD) by vortexing. The re-
suspended pellets were re-centrifuged as indicated above and re-
suspended in 100 mL of 2M solution of ammonium hydroxide
(obtained from a diluted 5N ammonium hydroxide volumetric
standard, Sigma-Aldrich, St. Louis, MO, USA). Specimens were
vortexed vigorously, incubated at room temperature for 10
minutes and vortexed again. If the pellet had not dissolved, it
was solubilized by repeat pipetting and continuous cycle of
vortexing until dissolved. Each specimen was placed into a heating
block and heat-treated at 95–100 uC for 1 hour, or until the
ammonia had evaporated (dry tubes). Dried specimens were re-
suspended in 500 mL of molecular reagent-grade water and,
vigorously vortexed and incubated at room temperature for $30
minutes to ensure that any precipitate had re-dissolved. The
extracts were stored at 4 uC and tested within 24 h. The above
extracted samples and standard curves were prepared and
amplified in duplicate on two different days (4 data points) by
Real-time qPCR.
Real-time qPCR was performed using a previously described
method [20,21] targeting one sequence coding for ORF1 of the
Chlamydia cryptic plasmid [20,21]. This method was previously
demonstrated highly reproducible (R
2=0.998) and with analytical
sensitivity of ,10 copies per amplification [21]. The previously
described reproducibility was established against eleven standard
curves constructed for the EB standard on different days. Each
curve was generated from seven serial 10-fold dilutions of the
pCTL12A plasmid amplified in duplicate. In addition, previously
published data showed that 7.7260.68 (mean 6 SD) plasmid
copies corresponded to one elementary body of C. trachomatis
(serovar L1), consistent with previously obtained values [20].
Analysis of genital clinical specimens revealed a strong correlation
(R
2=0.929) between elementary body counts determined by a
quantitative ligase chain reaction (LCR)–based Chlamydia tracho-
matis LCx Assay (Abbott Laboratories) which targets a conserved
region of the cryptic plasmid and those determined by the current
qPCR method [20]. Although most of the infected patients were
likely to harbour C. trachomatis serovars A, B, Ba and C, the primer
sets for both Amplicor and qPCR assays correspond to conserved
regions of the C. trachomatis cryptic plasmid and are therefore able
to detect all C. trachomatis serovars. Through the present analysis,
the organism load was expressed in number of plasmid per swab
and not in EB per swab even though, to the knowledge of the
authors, it has not been reported that the number of cryptic
plasmid significantly varies between serovars. In addition, the
second swab from patients identified as Amplicor-positive and 50
randomly selected Amplicor-negative samples with or without
clinical signs were tested in duplicate with the 16S-RNA assay.
The second swabs were tested in a masked fashion (randomised
order) by Amplicor and the 16S-RNA assay. Sample that yielded a
positive result on the first swab, but was negative on the second
swab, was re-tested in a chessboard manner in presence of known
positive and negative samples and, positive and negative controls.
Amplification of RNA extracted samples (total RNA RNeasy
Mini Kit, QIAGEN Inc. Valencia, CA, USA) were performed by
isothermal amplification and amplified products detected visually
on a dipstick as described previously [18,19,24,25]. The test
designated as SAMBA (Simple AMplification-Based Assay) is
based on a proprietary technology [18,19]. Primer and probe
target conserved sequences for all the 16sRNA Chlamydia trachomatis
serovars obtained from the American Type Culture Collection
(ATCC; MD, USA). Regions are conserved for all Chlamydia
trachomatis serovars and were selected as previously described for
the diagnosis of 2009 pandemic influenza (H1N1) [25] with
sequences obtained from the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov) and analysed with
Jalview 2.3 (University of Dundee, UK). Detector and capture
probes [24] were also designed to target similarly these specific
regions. The primers and probes were compared with the
Nucleotide Collection database at NCBI with the use of the Basic
Local Alignment Search Tool (BLAST). Specificity was established
against a panel of microorganisms commonly associated with
human eye and skin (e.g. Staphylococcus, Pseudomonas, Strepto-
coccus, Escherichia, Proteus and Candida, obtained from ATCC).
The SAMBA Chlamydia in a closed device to prevent amplicon
contamination has the same unique characteristics of the
previously described SAMBA HIV-1 test chemistry render it
suitable for near-patient testing in both developed and developing
countries because the test uses thermostable reagents and a
simplified protocol with minimum sample processing [24].
In brief, after amplification, the amplicon was incubated in a
2 mL microcentrifuge tube at 41 uC on a heating block. 20 mLo f
amplification product were added to a proprietary detection
mixture and the dipstick was inserted in the reaction mixture. The
test results were examined after 25 min of incubation and signal
on the dipstick scored by an experienced operator according to the
in-house scoring chart [25].
To assess the quality of the sampling procedure, human
genomic DNA was quantified with Double-Dye Taqman kit
according to the manufacturer’s instruction (Primer Design,
Southampton, UK) in all PCR positive samples and 41 randomly
selected PCR-negative samples. The primers of human genomic
DNA kit detect a single copy region of non-transcribed DNA.
Statistical analysis
Statistical analysis was performed with SAS v9.1 software.
Confidence intervals (CI) were calculated as exact binomials. The
geometric mean of organism load as well as its respective standard
deviation (SD) and 95% confidence interval (CI) for the ocular
swabs were calculated from the natural log transformation of the
organism load obtained for each swab. The organism load of the
ocular samples was compared between the first and second grades
of the clinical signs by the Student’s t-test, unequal variance t-test
Satterthwaite and equal variance pooled t-test. The correlation
between organism load and the fine grading scheme, the load first
swabs and the organism load of seconds swabs, and organism load
between the different population was obtained using Spearman
Rho (R) coefficients and paired Wilcoxon rank tests. Reliability of
PCR positivity of both swabs or with 16S-RNA positivity was
assessed with the kappa coefficient and its 95% confidence
intervals. A p-value of ,0.05 was considered statistically
significant.
Results
Fine grading scheme of the clinical signs
We examined 1316 of 1545 potential participants, giving an
overall examination rate of 85.2% (Figure 1). A total of 1282
participants were eligible for this analysis with a median age of
17.1 years (range: 0.1–95). Each participant was assessed for
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[15]), by PCR (Roche) and by the LPS-based POC assay.
On the basis of clinical examination of both eyes of each subject,
135 participants had active trachoma (10.5%; 95% CI: 8.9–12.2),
130 with TFWHO and five had TIWHO without TFWHO. Taking
the findings of both eyes the highest age-specific prevalence of TF
was in children 2–4 year-old (33/121; 27.3%) followed by 5–9
year-old (51/229; 22.3%) and those with less than 2 years of age
(13/61; 21.3%). The overall prevalence of TFWHO in children
aged 1–9 was 25.1% (96/383, 95% CI: 20.7–29.4) and the
prevalence of the five communities ranged from 9.8% to 38.5%
(4/41 [9.8%], 5/49 [10.2%], 23/115 [20.0%], 27/82 [32.9%]
and 37/96 [38.5%], respectively).
In contrast, when clinical data were limited to the left eye in
order to directly compare with the PCR and POC testing results,
the frequency of clinical signs of active trachoma decreased to
8.6% (110/1282), 108 with TFWHO and two had TIWHO without
TFWHO (Table 2). The resulting prevalence in the five commu-
nities in children aged 1–9 was 0/41 (0%), 4/49 (8.2%), 21/115
(18.3%), 21/82 (25.6%) and 36/96 (37.5%).
NAAT-positivity
The PCR (Amplicor) positivity rate in the population was 3.6%
(46/1282, 95% CI: 2.6–4.6) and, in children aged 1–9, 6.8% (26/
383, 95% CI: 4.3–9.3). Of the PCR positive participants, the
highest rate was in children 5–9 year-old (17/46; 37%) followed by
2–4 year-old (9/46; 19.6%) and 10–14 year-old (8/46; 17.4%,
Figure 2). Of the 46 people for whom the first swab from the left
eye was PCR-positive, on testing of the second swab, 43 (93.5%,
95%CI: 86.3–100) were PCR-positive and 44 (95.7%) were 16S-
RNA-positive. Two of the three PCR-negative second swabs were
16S-RNA-positive and one of those had the lowest organism load
on the first swab. There was a good agreement between the first
and second swabs tested with PCR (kappa coefficient 0.97; 95%
CI: 0.93–1.00) and between the first swab PCR and the 16S-RNA
result (kappa coefficient 0.98; 95% CI: 0.95–1.0).
The CT organism load was analysed by qPCR in all PCR-
positive swabs (Figure 3). The geometric mean organism load was
55,585 (95%CI: 801–3,811,754) pCTL12A plasmid per swab for
the first swab and 4,355 (95%CI: 98–193,602) for the second. The
mean organism load for the second swab was 12.8 times lower
(95%CI: 0.79–566.3) than for the first (paired Wilcoxon rank sum
test, P,0.0001). The organism load in the first swab was strongly
correlated with the load in the second swab (Spearman Rho=0.74,
P,0.0001).
Toconfirmtheadequacyofspecimen collection,humangenomic
DNA was quantified for the 46 PCR-positive (1.2560.69 mgo f
genomic DNA/swab)and41 randomPCR-negative(includingnine
participants presenting signs of TFWHO – 1.3360.70 mg of genomic
DNA/swab). The amount of genomic DNA was not significantly
different between positive and negative ocular samples (two-tailed
P=0.6), nor was there a correlation between the organism load and
the quantity of genomic DNA/swab. All of the 32 control swabs of
potential formites were negative by PCR.
NAAT-positivity versus clinical signs
A significant correlation was observed between PCR-positivity
(Amplicor) and TFWHO (Wilcoxon rank sum tests P,0.0001) and,
between PCR-positivity and the fine grading scheme (Spearman
Rho=0.98 and P=0.0004) (Table 2). A higher proportion of
people were PCR positive as clinical disease, as assessed by the fine
grading, became more severe. However, it should be noted that
59% (27/46) of PCR positive results occurred in people with
TFWHO, although only 13% (6/46) occurred in people with TF0.
As result, the agreement between PCR and TFWHO was poor
for children of #9 year of age (k=0.15; 95% CI: 0.01–0.25) and
Figure 1. Recruitment algorithm for participants in five Aboriginal communities.
doi:10.1371/journal.pntd.0000986.g001
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Figure 4 describes the age-specific prevalence of the left eye fine
grading of TF1 (Figure 4A), TF2 (Figure 4B), TF3 (Figure 4C) and
TF4 (Figure 4D) versus PCR positivity.
Of particular interest were six PCR positive participants who
had not have active follicular disease and were graded as TF0. All
were female whose ages were 9, 16, 21, 57, 66 and 73 years. Two
lived in houses with children who were PCR positive. Another two
lived in houses in which three or more children had TF3. The fifth
woman was aged 73 and had TI1 and TS3 with 30,918 plasmid/
swab. She shared a house with two men, one aged 28 who had
TF2 and TI1 and the other aged 58 with TF1 and TI1. The sixth
was a 9 year-old girl with a normal exam and 37,074 plasmid/
swab whose house number was missing so her household contacts
could not be identified. Therefore, with the exception of the last
girl, a plausible case can be made for exposure to infection and
four of five had some signs of inflammation (TI of some degree).
Organism load versus clinical sign
The fine grading of TF0–4 (Figure 5A), TI0–4 in presence of
TFWHO (Figure 5B), TI0–4 in absence of TFWHO (Figure 5C) and
TS0–4 in presence of TFWHO was positively correlated with the
organism load whereas there was no correlation for TS0–4 in
absence of TFWHO (Spearman Rho (R)=0.498 and P=0.0004,
R=0.473 and P=0.0009, R=0.438 and P=0.0023, R=0.449
and P=0.0017 and R=20.039 and P=0.7946, respectively). The
Table 2. Clinical signs of active trachoma compared with the presence of C. trachomatis.
Clinical signs of active trachoma (TF and TI) in the left eye compared with the presence of C. trachomatis DNA by PCR and the POC test positivity
Clinical sign PCR Positive (n=46) POC Positive (n=14) Total
and photograding n % 95% CI
1 n % 95% CI
1 (n=1282)
TF0 6 0.8 0.3–1.7 0 0.0 0.0–0.4 793
TF1 16 6.2 3.8–9.9 2 0.8 0.0–3.0 257
TF2 5 4.0 1.5–9.3 1 0.8 0.0–4.9 124
TF3 16 16.3 10.2–25.0 9 9.2 4.7–16.7 98
TF4 3 30.0 10.3–60.8 2 20.0 4.6–52.1 10
TFWHO absent 27 2.3 1.6–3.3 3 0.3 0.1–0.8 1,174
TFWHO present 19 17.6 11.5–25.9 11 10.2 5.6–17.5 108
2
TFWHO &T I WHO present 6 66.7 35.1–88.3 3 33.3 11.7–64.9 9
TIWHO present without TFWHO 1 50.0 9.5–90.6 1 50.0 9.5–90.6 2
Active trachoma 20 18.2 12.0–26.5 12 10.9 6.2–18.3 110
3
195% Confidence intervals were calculated with the adjusted Wald interval method.
2108 participants had TFWHO, 99 with TFWHO and nine had TFWHO with TIWHO.
3110 participants had active trachoma, 108 with TFWHO and two had TIWHO without TFWHO.
doi:10.1371/journal.pntd.0000986.t002
Figure 2. Age distribution of PCR-positive subjects (n=46/1282).
doi:10.1371/journal.pntd.0000986.g002
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133,252 plasmid/swab (95% CI: 2,173–8.2610
6), TFWHO absent
26,903 plasmid/swab (95% CI: 534–1.4610
6), TIWHO present
400,312 plasmid/swab (95% CI: 38,101–4.2610
6) and TIWHO
absent 40,135 plasmid/swab (95% CI: 655–2.5610
6).
POC assay
The LPS-based POC assay yielded 18 positive individuals, 14
were PCR positive and 4 were young adults who were PCR
negative and without clinical disease (TF0 and TI0). Using PCR as
the comparator test, the sensitivity and specificity of the POC was
30.4% (14/46, 95% CI: 17.1–43.7) and 99.7% (1232/1236, 95%
CI: 99.4–100), respectively.
Discussion
The poor correlation between the prevalence of clinically active
trachoma and evidence of infection is not new [12,13], especially
in low prevalence communities [5]. As with any infectious disease,
there is an initial incubation period (4–8 days) between inoculation
and the development of clinical disease [5]. This is followed by
frank disease when both bacterium and clinical signs co-exist, and
a later stage when the infection is no longer present or cannot be
detected by diagnostic tests, yet the clinical signs persist as disease
slowly resolve [5,26]. In humans, the lag period between the last
detectable bacterial shedding and the resolution of the active
disease may take up to 9 months or so [5,27]. As previously
observed [7], the prevalence of active trachoma varies when one
or both eyes are considered, in this study from 8.6% to 10.5%,
respectively [7,28]. For practical and economic reasons, swabs for
PCR, LPS-based and 16S-RNA testing, and photographs were
only collected from the left eye. Therefore, clinical/laboratory
diagnostic comparisons were made only for the left eye using the
consensus grading based on clinical and photographic data.
To reduce the likelihood of over-grading of clinical disease, the
assessment was made both in the field using frequent reference to
the WHO grading card and by independent photo-grading.
Although over-grading can still occur, this combined approach
reduces the risk.
A comparison of the performance data of the LPS-based POC
with an analytical sensitivity of 2,500 chlamydial elementary bodies
[7] from Tanzania and the current study in Australia is interesting.
Although the prevalence rates of TFWHO in 1 to 9 year olds are
roughly comparable; 28% and 21% respectively, the intensity of
disease (the proportion of those with TF and/or TI who have TI)
was nearly three times higher in Tanzania (25% compared to 9.5%)
as was the mean organism load (147,267 compared to 55,585
plasmids/swab). The unequal variance t-test Satterwaite using load
(P=0.0057) and equal variance pooled t-test using natural log
transformation of the organism load indicated (P=0.0333) that
organism load difference between those samples collected in
Aboriginal communities and those samples collected in the Masai
Figure 3. Distribution of the organism load
1 in first and second swabs showing the geometric mean
2.
doi:10.1371/journal.pntd.0000986.g003
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disease in Australia is reflected in the two to three times lower rates
of PCR positivity in both those with TFWHO (16% in Australia and
44% in Tanzania) and those without TFWHO (4.3% and 9.7%).
Similarly the reduced performance of the LPS-based POC assay in
Australia may in part reflect the lower organism load and in part the
modification of the test. The reduced disease severity and infectious
load observed in Australian Aboriginal communities may reflect the
dramatic differences in medical, environment and living conditions
between the Masai and Aboriginal people.
Even though the detection of infection by PCR is a poor
predictor of the presence of clinical disease and equally clinical
disease was poorly correlated with infection, organism load was
strongly correlated with the prevalence and severity of active
trachoma as graded by the finer grading scheme and that 46% of
infection was found in people who did not have the WHO grade of
TF but who still had some milder clinical changes (TF1 or TF2). As
mentioned, organism load also correlated with the fine grading of
trachoma. Similar findings come from an earlier study that used a
roughly similar finer grading scheme and that used both tissue
culture and direct fluorescent antibody cytology to detect infection
[13]. That study also found the load of infection was higher in
those with more severe disease (WHO grade TF) than in those
with less severe clinical disease.
In that study with a less sensitive assessment of infection 12% of
infection was in those who did not have the simplified WHO grade
of TF or TI. A rapid, simple and affordable POC test capable of
accurate identification of active infection would nevertheless be a
useful tool in trachoma control. The 16S-RNA test, a closed-
system device based on visual detection of nucleic acid on a
Figure 4. Age-specific prevalence of the left eye fine grading of TF and PCR positivity. Fig. 4A: Sign of TF1; Fig. 4B: Sign of TF2; Fig. 4C:
Sign of TF3; Fig. 4D: Sign of TF4.
doi:10.1371/journal.pntd.0000986.g004
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1; Fig. 5B: TI0–4 in presence of TFWHO vs. load
2; Fig. 5C:
TI0–4 in absence of TFWHO vs. load
3.
doi:10.1371/journal.pntd.0000986.g005
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and thermostability and therefore has the potential to meet this
need [29,30]. Because of the sealed containment of amplified
sample a dedicated laboratory is not require. Assay reagents have
been converted into thermostable formulas (stability tested at 55
uC for one month and 37 uC for 12 months, data not shown) and
the test uses a simplified protocol with minimum operation and
sample processing made possible by a disposable modular
cartridge previously described by Lee et al [24]. This technology,
Simple Amplification-Based Assay (SAMBA) has a substantial
advantage over currently available NATs, in that it is able to
provide results quickly and on-site, thereby facilitating appropriate
clinical support. The simplicity of SAMBA tests will allow their use
in resource-poor settings in developing countries and for near-
patient testing in the developed world [24]. These features may
offer advantages over the LPS-based POC, although further
evaluation of the 16S-RNA Chlamydia SAMBA test in areas of
varying trachoma prevalence is required to better assess its
performance and cost effectiveness.
Of considerable interest is the small number of individuals who
had a positive PCR in the absence of a detectable follicular
response (TF0). Some were older people with scarred conjunctiva
who may be incapable of mounting such an immune response.
Others may have had a transitory infection or may have been in
an incubatory phase of infection. As demonstrated in this study, a
rational explanation for a possible source of infection was
identified in the household in all but one case. In this case an
elderly woman who was PCR positive shared a house with two
other adults. A treatment program that only targeted households
with children would miss treating households such as this.
However, a significant problem in these communities is the
frequent sharing of houses and it is not unusual for children to
sleep in two or three different houses each week [5]. We were not
able to track this sort of movement to identify extended families.
More precise data of people’s movements and behaviour would be
needed to explore this in further detail.
The strengths of this study include firstly the careful
documentation and quantification of the two outcomes, the
presence of infection and clinical trachoma. Careful specimen
collection and handling limited sampling cross-contamination
critical when highly sensitive NAATs capable of detecting low
level of targets are used. Poor sampling methods and risk of cross-
contamination in the field have caused concern about the validity
of some early NAAT findings [5,31]. We observed no significant
difference between the quantity of human genomic DNA
contained in negative and positive PCR swabs that makes
inadequate sample collection unlikely. The repeat negative control
swabs of fomites suggest that the field precautions taken to prevent
cross-contamination were successful. Further, the positioning of
the samples in the test plate was verified to ensure that neither
positive specimens nor positive controls were adjacent on repeat
testing. Quantitative PCR was used to assess the infectious load in
all positive specimens.
Secondly, this study used a fine or semi-quantitative scale to
grade the clinical severity of trachoma and developed a consensus-
based grade that used both clinical and photographic findings.
This allowed for a much more detailed assessment of the presence
of clinical signs and the recognition of less advanced disease than
the more frequently used WHO simplified trachoma grading
system [14]. The use of a finer grading scheme is especially
important in detailed research studies looking for correlation
between clinical disease, environmental or genetic risk factors and
the distribution of infection in a community when attempts are
made to separate those with ‘‘disease’’ from those who are
‘‘asymptomatic’’. A finer grading scheme allows the identification
of subjects with clinical signs below the threshold set by the
simplified WHO grading scheme because many people with less
advanced disease do not fit in the clear-cut definitions used in the
WHO simplified trachoma grading system.
Finally, this study was a population-based study with high
community coverage that included people of all ages.
Potential weaknesses include the inability to precisely link the
exposure to infection of individual participants as in these
communities children in particular may move frequently from
one house to house another. In addition, there were inevitably
some missing data for both people and house numbers. The study
did not assess the sampling, testing, clinical-grading and photo-
grading agreement between swabbers, laboratories and examiners
because the same swabber, laboratory and clinical-grading or
photo-grading examiners were used throughout the study. The
inter-operator agreement and intra-operator reproducibility of the
LPS-based test [7] and clinical- versus photo-grading agreement
[15] have been described elsewhere.
However, the key messages of this study are that the use of a
binary grading system like the simplified WHO grading system will
miss many of the more subtle issues around the identification of
chlamydial infection and clinical status [13]. Specifically, 53% of
the clinical disease (TF1 or TF2) and 59% of PCR positivity
occurred in people with disease less severe than the WHO grade of
TF. These data suggest that detailed studies of the pathogenesis,
distribution and natural history of trachoma should make use of
both a finer grading scheme and also quantify the infectious load.
The fine grading also revealed a high proportion of people with
clinical disease who were below the WHO threshold for TF. Most
of the active trachoma was seen in the younger children who also
had the more severe disease. Both the severity and prevalence of
TF decreased with age. However, the finding of a significant
proportion of people with few follicles, TF1 is noteworthy.
Although some of this will reflect the waxing and waning of
active trachoma, it suggests that in some people at least a few
follicles, once formed, may persist for a long period of time or
indefinitely. It is unclear whether these ‘‘persistent’’ follicles reflect
occasional exposure to chlamydial antigens or infection or if they
are a permanent tissue change.
Organism load varies in areas with different levels of endemicity
and intensity of disease. In areas with a lower prevalence or
intensity, laboratory tests may be of limited used for community-
based assessment. However, it is in these situations that these tests
would be of most use for the confirmation of sporadic cases with
clinical disease. In addition, when the upper tarsal conjunctiva was
swabbed transversally to collect an appropriate specimen for
testing, the organism load of the consecutive swab was
dramatically decreased even though the amount of collected cells
was similar. This great disparity in organism load raises concerns
about the use of consecutive specimens in preference to split
specimens.
The second generation NAATs capable of detecting high
multiple-copy of targets such as ribosomal rRNA should enhance
analytical sensitivity [32]. This may enable to detect some low
level infection previously missed by PCR [32,33] or other less
sensitive methods such as Real-time qPCR targeting a single copy
genomic sequence such as the major outer membrane protein
gene (omp1) or the outer membrane complex B protein gene (omcB)
instead of the multiple-copy sequences (Chlamydia cryptic plasmid),
LPS-based rapid test [7], culture and direct immuno-fluorescence
(DFA), and so extend the period of detectable infection. A point-
of-care nucleic acid amplification test based on targets with
multiple copies such as 16S-RNA would be a more appropriate
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www.plosntds.org 10 March 2011 | Volume 5 | Issue 3 | e986tool to detect low level of infection previously missed by LPS-based
rapid test [7].
Finally, the current prevalence of both active trachoma and
trichiasis are roughly similar to that reported 30 year ago in this
region by National Trachoma Eye Health Program [15] and both
of which exceed the thresholds set by WHO to define blinding
trachoma as a public health problem indicate the need for
appropriate interventions to control trachoma and prevent
blindness in these five Aboriginal communities.
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